Novavax (NASDAQ:NVAX) shares surged 5.85% in pre-market trading following the release of its third-quarter 2025 financial results, which significantly exceeded analyst expectations. The biotechnology company reported stronger-than-anticipated earnings and revenue, boosted by milestone payments related to its COVID-19 vaccine partnerships.

The company reported a quarterly loss of $(1.25) per share, beating the analyst consensus estimate of $(1.33) by 6.3%. While this represents a 64.47% increase in losses compared to the same period last year, it still outperformed expectations. More impressively, Novavax's quarterly revenue came in at $70.445 million, surpassing the analyst consensus estimate of $42.133 million by a substantial 67.20%. Despite being a 16.64% decrease from the same period last year, the revenue beat appears to have sparked investor optimism.

Adding to the positive sentiment, Novavax provided a full-year adjusted total revenue outlook of $1.04 billion to $1.06 billion, aligning with the IBES estimate of $1.05 billion. This guidance suggests confidence in the company's financial performance for the remainder of the fiscal year. The strong quarterly performance and optimistic outlook likely contributed to the significant pre-market stock price increase, as investors react positively to Novavax's ability to exceed expectations and maintain a solid financial position in the competitive biotech landscape.